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Summary
Objective: Adult mesenchymal stem cells (MSCs) are multipotent cells whose primary reservoir is bone marrow (BM). Following situations of
extensive tissue damage, MSCs are mobilized and migrate to the site of injury. Osteoarthritis (OA) is a condition that involves extensive car-
tilage and bone damage. To gain insight into the pathogenesis of OA, we have analyzed the differential BM-MSCs proteome of OA patients.
Methods: MSCs protein extracts were prepared from BM aspirates from six patients with OA and from six hip fracture subjects without OA, and
analyzed by Two-dimensional gels, using the differential in-gel electrophoresis approach. Differentially expressed proteins were identiﬁed by
mass spectrometry. In addition, the chemotactic responses of OA and control MSCs were assessed.
Results: The majority of proteins that changed at least 1.5-fold (P< 0.05) belonged to the following three categories: metabolic enzymes (14
proteins, 36%), cytoskeleton/motility (12 proteins, 32%), and transporters (three proteins, 8%). In OA MSCs, a high percentage of metabolic
enzymes (n¼ 8, 57%) were up-regulated and most of the proteins related to cytoskeleton/motility (n¼ 9, 75%) were down-regulated. There
was a signiﬁcant increase in the migration response of OA MSCs to platelet-derived growth factor-BB (chemotaxis index CI: 5.13 1.19 vs
3.35 0.42, P¼ 0.043).
Conclusions: In this study, we have described the differential proteome of BM-MSCs from OA patients together with an increased chemotactic
response of these cells in the context of OA. These results could indicate an activation of OA BM-MSCs in response to chemotactic signals
sent by the altered subchondral bone in an attempt to heal damaged tissue.
ª 2007 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
Key words: Osteoarthritis, Mesenchymal stem cells, Proteomics.Introduction
Osteoarthritis (OA) is a degenerative joint disease charac-
terized by pain, cartilage loss, and joint stiffness. Although
OA has long been considered to be primarily a cartilage dis-
order associated with focal articular cartilage degradation,
this disease is accompanied by well-deﬁned changes in
the subchondral and periarticular bone, including sclerosis
and cyst and osteophyte formation1. Recent studies have
demonstrated increased subchondral bone turnover ac-
companied by speciﬁc architectural changes in the sub-
chondral trabecular bone in OA joints2. Furthermore,1This work was supported by grants from FMMA and FIS
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929epidemiologic studies have clearly documented increased
subchondral bone sclerosis with disease progression3.
Mesenchymal stem cells (MSCs) exhibit a multipotent dif-
ferentiation potential and can give rise to mesodermal de-
rived tissue such as bone, cartilage, tendon and muscle4.
The bone marrow (BM) serves as the primary reservoir for
MSCs, although their presence has been reported in a variety
of other tissues, including fat, synovial membrane, and carti-
lage4. MSC migration is critically associated with damaged
tissue remodeling5. In response to tissue damage, MSCsmi-
grate into damaged sites along a chemotactic gradient5.
Two-dimensional gel electrophoresis (2DE) with immobi-
lized pH gradients (IPGs)6 combined with protein identiﬁca-
tion by mass spectrometry (MS)7 can be routinely applied
for parallel quantitative expression proﬁling of large sets of
complex protein mixtures such as whole cell lysates. Gel
electrophoresis (2D) enables the separation of complex
mixtures of proteins according to their isoelectric point
(pI) and molecular weight (Mw). Furthermore, it delivers
a map of intact proteins that reﬂects changes in protein ex-
pression levels, isoforms or posttranslational modiﬁcations.
Some limitations of the 2DE technique are low sensitivity,
930 R. Rollı´n et al.: Proteome of bone marrow MSCs in OAreduced dynamic range and gel-to-gel variability. Recently,
2D ﬂuorescence differential in-gel electrophoresis (2D-
DIGE)8 technology has made it possible to quantify the dif-
ferences between two or three protein samples resolved on
the same 2D gel, enabling a more accurate, sensitive and
rapid analysis of differences, and providing a more powerful
tool to quantitate protein expression changes under dis-
eased conditions. This technique is based on the pre-elec-
trophoretic labeling of samples with one of two spectrally
different ﬂuorescent dyes, CyDye 3 (Cy3) or Cy5, whereas
a third spectrally different ﬂuorescent dye, Cy2, is used to
label a pooled sample, the internal standard, comprising
equal amounts from all biological samples in the experi-
ment. After tagging, the two samples and the internal stan-
dard are mixed together and run on the same 2D gel. The
internal standard is loaded in all the gels, and spot volumes
are calculated in terms of the ratios of Cy3- and Cy5-tagged
spot volumes to the standard Cy2 volume. With 2D-DIGE,
many sources of experimental variation are reduced by
the inclusion of the internal standard on each gel, allowing
both intra- and inter-gel matching9,10.
Therefore, to gain insight into the pathogenesis of OA we
have studied the speciﬁc alterations in the proteome of
MSCs by using 2D-DIGE and MS. This study was focused
on characterizing the differential proteome of BM-MSCs
from patients with OA by comparing it with the correspond-
ing proteomic proﬁles of MSCs from hip fracture subjects
without OA. Chemotactic responses of MSCs have been
also studied in order to analyze the migratory capacity of
these cells in the context of damaged tissue as the altered
subchondral bone of OA patients.
MethodsPATIENTS AND SPECIMENSBM aspirates were obtained from the femoral channel of six OA patients
(mean age 74.7 years, range 61e89) at the time of surgery for total knee
arthroplasty and from six hip fracture subjects without OA (mean age 66.6
years, range 44e90) during hip joint replacement surgery for the treatment
of subcapital fracture. The diagnosis of knee OA was based on American
College of Rheumatology (ACR) criteria11,12. Although hip fracture subjects
without OA were not tested for bone status, we have reasonably ruled out
osteoporosis in this group by selecting individuals on the basis of the fol-
lowing criteria: they failed to show radiographic signs of OA; no diagnosis
of osteoporosis was found in their clinical records; patients had not been
taking any treatment related to prevention or induction of osteoporosis; their
hip fracture was provoked after a traumatism strong enough for developing
such a fracture in this elder population. All samples were obtained after pa-
tients gave their informed consent, and this study was approved by the lo-
cal institutional ethics committee.CELL-CULTUREThe isolation and culture expansion of MSCs were carried out as previ-
ously described13. Brieﬂy, the aspirates were washed once with Dulbecco’s
modiﬁed Eagle’s medium-low glucose (DMEM-LG; Gibco BRL, Paisley, UK)
containing 10% fetal bovine serum (FBS) (SigmaeAldrich; St. Louis, MO,
USA) and antibiotic supplements (complete medium). The cell-containing
fraction was gently layered onto a 70% Percoll solution (SigmaeAldrich)
and centrifuged at 500g for 15 min at 23C. The low-density fraction was col-
lected, washed once with complete medium, and plated into a culture dish
(100 mm). At the end of primary culture, adherent colonies were detached
by treatment with 0.25% trypsin containing 1 mM ethylenediaminetetraacetic
acid (EDTA) for 5 min at 37C, and subsequently replated for continued pas-
saging at 1:2. Conﬂuent cells (approximately 2 106) at the third passage
were used for the experiments.PROTEIN SAMPLE PREPARATIONTrypsinized cells were washed with Phosphate-buffered saline (PBS) and
centrifuged. Pelleted cells were broken with lysis buffer (30 mM TriseHCl pH
8.5, 7 M urea, 2 M thiourea, 4% 3-[(3-cholamidopropyl)dimethyl-ammonio]-1-propanesulfonate (CHAPS), 50 mM Dithiothreitol (DTT)) and grinded with
resin and a pestle using the Grinding Kit (GE Healthcare). The proteins
were precipitated with the 2D Clean-Up Kit (GE Healthcare), resuspended
in lysis buffer without DTT, and the pH adjusted to 8.5 at 4C when neces-
sary. Protein concentration was measured with the RCDC Protein Assay
Kit (Bio-Rad).DIGE LABELING AND 2D ELECTROPHORESISProtein extract samples from OA patients and hip fracture subjects
without OA were labeled with CyDye DIGE Fluor minimal dyes according
to the manufacturer’s instructions (GE Healthcare). Brieﬂy, 50 mg of each
protein extract was separately labeled at 0C in the dark for 30 min with
400 pmol of the N-hydroxysuccinimide esters of cyanine dyes (Cy3 and
Cy5 CyDyes) dissolved in 99.8% Dimethylformamide (DMF) (Sigma).
The internal standard, the equimolecular mixture of all the protein extracts,
was labeled with Cy2 dye in the same way. The labeling reaction was
quenched by the addition of 1 ml of a 10 mM L-lysine solution (Sigma)
and left on ice 10 min. After labeling and quenching, OA patients, hip frac-
ture subjects without OA and internal standard protein samples were
mixed adequately (one of each condition per gel) and run in a single
gel. A volume of rehydration buffer (7 M urea, 2 M thiourea, 4% CHAPS)
containing 0.8% IPG buffer, pH 4e7, and 50 mM DTT was added to the
mixed samples.
Samples were then applied via cup loading to rehydrated 24-cm Immobi-
line DryStrip gels, pH 4e7, followed by isoelectric focusing (IEF) (ﬁrst-dimen-
sion) on an IPGphor II System (GE Healthcare) until steady state (42 kVh).
Second-dimension sodium dodecyl sulfate polyacrylamide gel electrophore-
sis (SDS-PAGE) separation was carried out on 12% polyacrylamide gels
(26 20 cm) prepared within low-ﬂuorescence glass plates. Electrophoresis
was performed using the Ettan DALT six electrophoresis system (GE Health-
care) at 2 W/gel for 1 h and 20 W/gel until the tracking dye had migrated off
the bottom of the gel, at 25C.IMAGE ACQUISITION AND ANALYSISAfter SDS-PAGE, the gels were scanned using a Typhoon 9400 vari-
able mode Imager (GE Healthcare) using appropriate wavelengths and ﬁlters
for Cy2, Cy3, and Cy5 dyes according to the manufacturer’s protocol. Scans
were acquired at 100-mm resolution. After cropping, relative protein quantiﬁ-
cation across all OA and hip fracture subjects without OA was performed us-
ing Decyder software. Initially, Differential In-gel Analysis (DIA) module was
used to co-detect the three images of a gel (internal standard and two sam-
ples), to provide a consistent and accurate spot ratio measurement in terms
of the ratios of the Cy3 and Cy5 spot volumes to the standard Cy2 volume on
each gel. Background subtraction, quantiﬁcation and normalization were au-
tomatically applied with low experimental variation. These images individu-
ally processed with the DIA module were matched between gels with the
Biological Variation Analysis (BVA) module, using the internal standard for
gel-to-gel matching. BVA was able to detect the consistency of differences
between experimental groups across all the gels. Each of the differences
was calculated as average ratios for each spot. Student’s t test was used
to compare average ratios for each spot between OA patients and hip frac-
ture subjects without OA. P values less than 0.05 were considered
signiﬁcant.
We performed an additional statistical analysis using Extended Data Anal-
ysis (EDA) module, and we could clearly observe that OA group was efﬁ-
ciently discriminated from hip fracture subjects without OA in relation to the
expression values of detected proteins (not shown).
Variance was used as a measure of variability and it was clearly observed
that variances were very low (see Supplemental material). In this scenario,
we have established a differential volume ratio of 1.5, together with a signif-
icant t test, as a cut-off for differential protein expression.SPOT EXCISION AND IN-GEL TRYPSIN DIGESTIONProtein spots that showed signiﬁcantly altered expression levels between
the two groups by DeCyder Differential Analysis Software and EDA were se-
lected for gel excision. Protein spots from silver-stained gels were excised
manually, transferred to a 96-well microplate, and then digested automati-
cally using a Proteineer DP protein digestion station (Bruker-Daltonics,
Bremen, Germany). The digestion protocol used was that of Shevchenko
et al.14 with minor variations. The gel pieces were then rinsed with 50 mM
ammonium bicarbonate and acetonitrile (gradient grade; Merck, Darmstadt,
Germany) and dried under a stream of nitrogen. Modiﬁed porcine trypsin (se-
quencing grade; Promega 2800 Woods Hollow Rd. Madison, WI 53711-5399
USA), at a ﬁnal concentration of 8 ng/ml in 50 mM ammonium bicarbonate,
was added to the dry gel pieces and the digestion proceeded at 37C for
6 h. Finally, 0.5% triﬂuoroacetic acid (99.5% purity; Sigma) was added for
peptide extraction.
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SPECTROMETRY (MALDI-MS) (/MS) AND DATABASE
SEARCHINGAn aliquot of the above digestion solution was mixed with an aliquot of
a-cyano-4-hydroxycinnamic acid (Bruker-Daltonics) in 33% aqueous aceto-
nitrile and 0.1% triﬂuoroacetic acid. This mixture was deposited onto
a 600 mm AnchorChip MALDI probe (Bruker-Daltonics) and allowed to dry
at room temperature. MALDI-MS (and MALDI-MS/MS) data were obtained
using an Ultraﬂex time-of-ﬂight mass spectrometer (Bruker-Daltonics) equip-
ped with a LIFT-MS/MS device15. Detailed analysis of peptide mass mapping
data was performed using ﬂexAnalysis software (Bruker-Daltonics). MALDI-
MS and MS/MS data were combined through the MS BioTools program
(Bruker-Daltonics) to search the NCBInr database using Mascot software
(Matrix Science, London, UK)16.BIOLOGICAL FUNCTIONInformation about those proteins differentially regulated in MSC from OA
patients was retrieved from different proteomics servers (RCSB Protein Data
Bank, Babelomics, Expasy Proteomics Server, Information Hyperlinked over
Proteins, EBIMed) containing information from the main protein databases
(UniProt Knowledgebase, Prosite, IntAct, OMIM and NCBI).CHEMOTAXIS ASSAYConﬂuent MSCs from six OA patients and six hip fracture subjects without
OA were trypsinized, counted, and then washed once by centrifugation. Che-
motaxis responses were measured using 24-well cell-culture chambers
(Transwell Permeable Supports; Corning, NY, USA), with inserts of 6.5-
mm-diameter and 8-mm pore polycarbonate membranes. Cells (2 104) in
0.1 ml DMEM were seeded on the upper chambers and incubated for 2 h
at 37C in 5% CO2 to allow cell attachment and spreading. After the cells
had attached to the Transwell membranes, 0.6 ml culture medium contain-
ing 1 ng/ml rhPDGF-BB (R&D Systems Inc. 614 McKinley Place N.E.,Fig. 1. 2D-DIGE of MSC proteins. Each individual sample (OA and hip f
labeled with Cy5, Cy3 and Cy2, respectively, mixed, and separated on
Cy3 (B) and Cy2 (C) images were obtained from each gel. AnMinneapolis, MN 55413 USA) was added to the lower compartment. Follow-
ing 4 h of incubation at the same temperature, the cells on the upper surface
of the membrane were removed with a cotton swab, and the remaining mi-
grated cells on the lower side of the ﬁlter were ﬁxed with 4% formaldehyde
and stained with crystal violet. Control wells with only DMEM in the bottom
well were included in each experiment. All measurements were from at least
six independent experiments performed in triplicate.
The number of migrated cells in the control and stimulated wells was
counted for 10 random ﬁelds per well at 100 magniﬁcation. Results were
expressed as a chemotactic index (CI). This index was determined as the av-
erage number of migrated cells in stimulated wells divided by the average
number of migrated cells in control wells.
The normality of variables was estimated using the ShapiroeWilk test.
Data were statistically analyzed with the ManneWhitney U test for compar-
ison of the two groups. Results are presented as means standard deviation
(SD). A value of P< 0.05 was considered statistically signiﬁcant.Results2D-DIGEWe analyzed by 2D-DIGE the MSCs proteome from
a group of 12 individuals, six OA patients and six hip frac-
ture subjects without OA. Figure 1 shows a representative
differential CyDye staining of MSCs proteins, with proteins
from one OA sample stained in green (Cy3), proteins from
one hip fracture subject without OA stained in red (Cy5),
and the internal standard stained in blue (Cy2).
Globally, 2384 92 spots (meanSD; n¼ 6, OA; n¼ 6,
hip fracture subjects without OA) were detected on each
analytical gel loaded with 50 mg of total protein lysate per
sample type (control or OA).racture subjects without OA) and a pooled reference sample were
a 2D-PAGE gel. Gels were scanned and a set each of Cy5 (A),
overlay of three dye scan-images was also obtained (D).
932 R. Rollı´n et al.: Proteome of bone marrow MSCs in OAOf the analyzed gel spots, we selected those fulﬁlling two
criteria: expression change by at least 1.5-fold compared to
control group and signiﬁcant t test (n¼ 6 in each group,
P< 0.05). The comparison between OA MSCs and hip frac-
ture subjects without OA resulted in the identiﬁcation of 73
signiﬁcantly different spots. The spots were excised manu-
ally from silver-stained gels and were identiﬁed by MS. A to-
tal of 61 protein spots of the 73 excised (83.6%) could be
unambiguously identiﬁed. The 2D silver-stained gel and
the 61 spots subject to protein identiﬁcation assays are
shown in Fig. 2(A). As illustrative examples, Fig. 2(B) shows
DeCyder Software 3D view of differentially expressed pro-
tein spots in MSCs from patients with OA, displaying in-
creased levels of cathepsin B, glucosidase, and stathmin,
and reduced levels of triosephosphate isomerase (TIM),
caldesmon, and vimentin.
Protein identiﬁcation results, together with the average ra-
tios and P values from DeCyder Differential Analysis, are
listed in Supplementary Table 1. Thirty-eight different pro-
teins were identiﬁed. Five of these were found in more than
one spot, corresponding to similar molecular masses with
different pIs: vimentin (gij340219 or gij57471646) was found
in spots 2, 4, 6, 8, 9, and 45; annexin V (gij999937) in spots
10e11; GRP78 (gij1143492) in spots 12 and 14; heat shock
protein 27 (gij662841 or gij54696638) in spots 16, 24, 27 and
38; and TIM 1 (gij17389815) in spots 46 and 58.
The proteins listed in Table I were classiﬁed into different
groups according to their biological function. Keratins (spots
17, 23, 32, 36, and 54) and albumins (spots 35, 39, 40, 42,
and 55) were excluded from the functional classiﬁcation.
The majority of proteins that changed at least 1.5-fold
(with P< 0.05) belonged to the following three categories:
metabolic enzymes (14 proteins, 36%), cytoskeleton/motil-
ity (12 proteins, 32%), and transporters (three proteins,
8%). A high percentage of metabolic enzymes (n¼ 8,
57%) were up-regulated in MSCs of OA patients, represent-
ing 50% of up-regulated proteins. Most proteins related to
cytoskeleton/motility (n¼ 9, 75%) were down-regulated in
OA patients, representing 41% of down-regulated proteins.
Figure 3 depicts the distribution of differential proteins ac-
cording to functional categories. A more detailed functional
classiﬁcation of the two main groups of differential proteins
in OA is shown in Table I.Fig. 2. (A) 2D silver-stained gels of MSC proteins. Spots for which the qu
change and a Student’s t test P value less than 0.05 in OA are shown in
spots were cut out of this gel and subjected to tryptic digestion followe
expressed protein spots in MSCs from patients with OA. Glucos: glucosi
vimentin; C: hip fracture sFUNCTIONAL ASSAY: CHEMOTAXIS OF MSCThere is much evidence to support the theory that MSCs
can home to tissues, particularly, when injured or inﬂamed,
involving migration across endothelial cell layers. The
mechanism by which MSCs home to tissues and migrate
across endothelium is not yet fully understood. Once in
the tissue, cells migrate along a chemokine gradient, which
involves the sensing of subtle differences in chemokine
concentrations and the establishment of cell polarity17,18.
Since subchondral bone, a potential source of chemotactic
factors, is damaged in OA and proteins differentially ex-
pressed in OA BM-MSCs were related to cytoskeleton
and metabolism, we have investigated the migratory capac-
ity of OA BM-MSCs under a chemotactic gradient.
Chemotaxis assays were performed using 24-well cell-
culture chambers (Transwell Permeable Supports; Corn-
ing, NY, USA), with inserts of 6.5-mm-diameter and 8-mm
pore polycarbonate membranes. The results of the Trans-
well Permeable Supports are shown in Fig. 4. Migration
of MSCs was stimulated by the addition of rhPDGF-BB,
as it has been described as a powerful chemotactic factor
for mesenchymal cells19. In a previous study carried out
by the same group20, rhPDGF-BB stimulated migration
with a different proﬁle in a dose-dependent manner with
a maximal chemotaxis index (CI) of 1 ng/ml. Here,
rhPDGF-BB (1 ng/ml) added to the bottom compartment
of the Transwell insert caused a signiﬁcant increase in mi-
grating MSCs from patients with OA compared to hip frac-
ture subjects without OA (CI: 5.13 1.19 vs 3.35 0.42,
P¼ 0.043). When identical amounts of rhPDGF-BB were
simultaneously added to the both the upper and the lower
compartments, the cell migration of MSCs remained
unchanged.Discussion
Over the past several years, different populations of MSCs
have been characterized using proteomic approaches.
These studies have deﬁned the temporal patterns of proteins
during morphological changes in MSC cultures, and have
identiﬁed differently expressed proteins responsible for
both osteogenic and adipogenic differentiation21e23.antitative statistical analysis revealed >1.5-fold protein expression
circles and numbered according to pI and Mw. The circled protein
d by MS analysis. (B) DeCyder Software 3D view of differentially
dase; Cath B: cathepsin B; Stath: stathmin; Cald: caldesmon; Vim:
ubjects without OA.
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933Osteoarthritis and Cartilage Vol. 16, No. 8In this study, we report, for the ﬁrst time, the differential
proteome of BM-MSCs from patients with OA vs hip fracture
subjects without OA. 2D-DIGE analysis combined with pro-
tein identiﬁcation by MS led to the identiﬁcation of 38 differ-
ent proteins. Fourteen (36%) out of these proteins are
metabolic enzymes, while 12 (32%) are related to cytoskel-
eton/motility.
The present study was focused on characterizing the dif-
ferential proteome of BM-MSCs from patients with OA by
comparing it with the corresponding proteomic proﬁles of
MSCs from hip fracture subjects without OA.
BM aspirates were obtained from six OA patients at the
time of surgery for total knee arthroplasty. The mean age
of our OA group was 74.7 years (range 61e89). We ﬁrst in-
tended to include in our study BM donors as a control
group; nevertheless, since BM donors are usually young
people and there are strong evidences that age diminishes
proliferative activity and osteogenic potential of BM-derived
MSCs, we chose OA and control group with comparable
ages. A control group with similar age comprised hip frac-
ture subjects without OA; we reasonably discarded osteo-
porosis in this group, but we could not completely rule out
this condition because adults in the age-range used for
our study may present with hip fracture after trauma as their
ﬁrst indication of osteoporosis and/or some of them may
have had undiagnosed osteoporosis. In spite of these limi-
tations, we considered hip fracture subjects without OA as
an appropriate control group in this scenario.
There is much evidence supporting the theory that MSCs
can home to some tissues, particularly when injured or in-
ﬂamed, involving migration across endothelial cell layers.
However, the mechanisms underlying migration of MSCs
remain to be clariﬁed24. Both site-directed and systemic de-
livery of MSCs have shown their engraftment in several tis-
sues including infarcted myocardium and neural tissue25,26.
Interestingly, site-directed delivery of MSCs has been suc-
cessfully used in the context of an OA caprine model27. In
addition, some data have been published supporting a recir-
culation of MSCs between BM and injured tissues28. These
ﬁndings point to the migratory capacity of MSCs, probably
in the context of chemoattractants, as a key event for tissue
repair by MSCs.
In our experiments, we have used platelet-derived growth
factor (PDGF) as chemoattractant, a polypeptide formed by
two amino acid chains of two related genes. It is a powerful
chemotactic factor for mesenchymal cells, including osteo-
blasts29. The products of the PDGF A and PDGF B genes
can form homodimers or heterodimers, so PDGF could
act in three isoforms: PDGF-AA, PDGF-BB, or PDGF-AB.
PDGF-BB may be more speciﬁc for MSCs and their recruit-
ment from long distances, being chemoattractive for the
progenitor cells even at the lowest concentrations19,20. In
this study, we assessed the chemotactic effects of PDGF-
BB on primary human MSCs from patients with OA and
compared the results with those of primary human MSCs
from hip fracture subjects without OA. Our results showed
a positive chemotactic response of MSCs to human
rhPDGF-BB. There was a signiﬁcant increase in the CI
(meanSD; six independent experiments) of the migration
response of OA MSCs to 1 ng/ml PDGF-BB. This signiﬁcant
increase in the motility of MSC of OA patients following che-
moattractant challenge with PDGF, together with the differ-
ential expression of metabolic and cytoskeleton proteins
could be related to an accelerated cell movement or motility,
a highly dynamic phenomenon that is essential to a variety
of biological processes including immune response and
wound healing17,18.
Fig. 3. Graphical representation of the functional classiﬁcation of proteins differentially expressed in MSCs from patients with OA and hip
fracture subjects without OA based on the data in Table I.
Fig. 4. Chemotaxis of MSC induced by PDGF-BB. Cells were
seeded in the upper compartment of a Transwell insert, and
1 ng/ml of PDGF-BB was added to the upper/lower compartments.
The cells were allowed to migrate for 4 h at 37C. The upper and
lower compartments were separated by a polycarbonate membrane
with 8 mm pores. Shown is the mean CI SD; P values from
ManneWhitney U test less than 0.05 were considered signiﬁcant
and marked by an asterisk (*).
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attractant, is coordinated spatially as well as temporally by
many proteins via mechanical changes in the cytoskeletal
structure and changes in the force production centers. It
is also related to actin regulatory proteins such as the
Arp2/3 complex through WASP family proteins, destrin/coﬁ-
lin down-stream of LIM-kinase, and various other phosphoi-
nositide-dependent or -independent pathways including
small GTPase Rho. Through branching of actin ﬁlaments,
Arp2/3 complex-dependent actin polymerization is sufﬁcient
to generate the force necessary for protrusion18.
Stathmin and destrin were differentially up-regulated in
MSC from OA patients. These two proteins work as key reg-
ulators of microtubule dynamics and actin polymerization. It
has been demonstrated that stathmin plays a signiﬁcant
role in patients with multiple sclerosis, favoring the migra-
tory phenotype of oligodendrocyte progenitors30. In addi-
tion, destrin appeared to be required for cell migration on
collagen I and for cell invasion through Matrigel in response
to the proinvasive neuroendocrine peptide bombesin in the
context of human colon cancer31. These facts connect, at
least in part, the up-regulation of stathmin and destrin with
the increased migratory capacity of MSC from OA patients
that we have observed.
Moesin, down-regulated in OA patients, is a member of
ERM family. ERM proteins appear to function as cross-
linkers between plasma membranes and actin-based
cytoskeletons. It has been demonstrated that cells lacking
moesin lose epithelial characteristics and adopt invasive
migratory behavior by antagonizing activity of the small
GTPase Rho, an essential protein to regulate signaling
pathways that mediate the distinct actin cytoskeleton
changes required for both cellular motility and cellecell
adhesion32. In addition, caldesmon, down-regulated in OApatients, is an actin-binding protein that inhibits the function
of gelsolin and Arp2/3 complex; these two proteins are
essential for the formation of podosomes, highly dynamic
actin-based structures commonly found in motile and inva-
sive cells33. Taken together, down-regulation of moesin and
caldesmon in OA is in agreement with the augmented mi-
gratory capacity of MSC in this condition.
Vimentin is down-regulated in MSC from OA patients.
Vimentin is the major intermediate ﬁlament protein of mes-
enchymal cells. It shows dynamically altered expression
935Osteoarthritis and Cartilage Vol. 16, No. 8patterns during different developmental stages and high se-
quence homology throughout all vertebrates, suggesting its
involvement in physiologically relevant roles. Vimentin
emerges as an organizer of a number of critical proteins in-
volved in attachment, migration, and cell signaling34. Hence
it can be hypothesized that down-regulation of vimentin in
OA patients is a result of multiple protein interactions re-
lated with different developmental stages and/or different
regulation protein networks in MSC.
In summary, we have described the differential proteome
of BM-MSCs from OA patients together with an increased
chemotactic response of these cells in the context of OA.
Our high-throughput proteomic approach based on DIGE
technology followed by MS analysis has produced a differ-
ential protein map on OA BM-MSCs. This proteomic ap-
proach can be regarded as a screening tool that needs
ulterior functional analysis as the performed chemotaxis as-
says. We could hypothesize that the increased chemotactic
response observed on OA BM-MSCs was due to a pre-
activation of these cells by signals sent by the subchondral
bone. Proteomic screening tools have demonstrated their
ability to ﬁnd differentially regulated proteins which might
serve to establish working hypothesis. These approaches,
together with functional analyses, could help to clarify the
underlying mechanisms involved in musculoskeletal dis-
eases as OA.Conﬂict of interest
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